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SUMMARY
Introduction: We wanted to characterize the evolution of
the COVID-19 pandemic in a typical metropolitan area.
Methods: Data were extracted from the Detroit COVID-19 Consortium database for hospitalized COVID-19 patients treated in Southeast Michigan over the
12-month period from March 2020 to February 2021.
Demographic and outcomes data were compared to
CDC data.
Results: A total of 4,775 patients were enrolled during
the study period. We divided the pandemic into three
phases: Phase-1 (Spring Surge); Phase-2 (Summer
Lull); and Phase-3 (Fall Spike). Changes in hydroxychloroquine, remdesivir, corticosteroid, antibiotic and
anticoagulant use closely followed publication of
landmark studies. Mortality in critically-ill patients

n INTRODUCTION

T

he severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has persisted into a second year. Michigan reported its
first two cases of COVID-19 disease on March
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decreased significantly from Phase-1 to Phase-3 (60.3%
vs. 47.9%, Chisq p=0.0110). Monthly mortality of all
hospitalized patients ranged between 14.8% - 21.5%
during Phase-1 and 9.7 to 13.4% during Phase 3 (NS).
Discussion: The COVID–19 pandemic presented in
three unique phases in Southeast Michigan. Medical systems rapidly modified treatment plans, often
preceding CDC and NIH recommendations. Despite
improved treatment regimens, intubation rates and
mortality for hospitalized patients remained elevated.
Conclusion: Preventive measures aimed at reducing
hospitalizations for COVID-19 should be emphasized.
Keywords: COVID-19, pandemic, metropolitan area,
prescr1ption.

10th, 2020, followed by a rapid acceleration of cases in Southeast Michigan taxing regional health
care systems [1]. A lull in cases occurred over the
summer months, followed by a surge of cases
in the fall [2]. At its peak in December 2020, the
state experienced more than 200 deaths per day
[2]. As of May 13th, 2021, Michigan has reported 969,452 cases of COVID-19 including 19,515
(2.0%) deaths, making Michigan one of the top
ten states for COVID-19 mortality since the pandemic began [2]. During the winter of 2020-2021,
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southeast Michigan remains at high risk, with an
average of 26 new cases per 100,000 population
daily [2]. Moreover, three counties in Southeast
Michigan (Wayne, Oakland, and Macomb) constitute 40% of the state’s new cases. We used southeast Michigan as a representative area of typical
metropolitan area as the population demographic
mix and the rise and fall of cases was similar in all
areas of the US.
As the pandemic evolved, various treatment protocols were proposed in the popular press and
medical literature [3-19]. Reports published in
the literature regarding the epidemiology, presentation, natural course and complications of
COVID-19 disease likely influenced local patterns of medical care everywhere in the world.
We sought to determine whether disease demographics evolved over the course of the pandemic, and how advances in medical knowledge affected frontline physician treatment plans and
outcomes. Utilizing data derived from the Detroit
COVID-19 Consortium database, we assessed
treatments and outcomes of patients admitted to
consortium hospitals in Southeast Michigan from
March 2020 through - February 2021, including a
comparison of outcomes during the initial Spring
Surge to those during the Fall Spike. We also present data about the evolution of clinical and demographic characteristics of the hospitalized patient
population.
n PATIENTS AND METHODS
Ethics Statement. Data collection for the consortium registry was approved under IRB#13785 at
Henry Ford Health System (HFHS), the Data Coordinating Center for the Detroit COVID-19 Consortium. A consortium agreement and data use
agreement are in place between Trinity Health
and HFHS. Secondary research for this proposal
was approved by Trinity Health under IRB #2020020. The study did not receive outside funding.
Contributing authors reported no conflict of interest.
Patient population. Data were collected from patients with PCR-confirmed COVID-19 admitted
to one of four participating hospitals of the Henry
Ford Health System or two participating hospitals of Trinity Health. All hospitals are located in
Wayne, Oakland or Macomb counties (Southeast
Michigan).

Study period. The presented data were collected
from March 1, 2020 through February 28, 2021.
Clinical data. Data were abstracted through automated reports of the electronic medical records
at contributing hospitals. The two systems submitted Michigan Health Information Network
ID numbers (MiHIN) so that data from patients
receiving care at both institutions could be linked.
The primary data points for this study, collected
by all systems, were patient characteristics: gender, primary race (Black, White, Other), age at
first admission (categorized as <40, 40-64, 65-80,
or >80 years); patient medical history including
co-morbidities, history of present illness (NIH
illness severity (moderate, severe, critical), Sequential Organ Failure Assessment (SOFA)/
Quick (q)SOFA score, clinical features at presentation); and medication use (antibiotics, anticoagulant, hydroxychloroquine, remdesivir, steroids;
etc). We stratified clinical outcomes by severity of
illness and the need for mechanical ventilation.
The Sequential Organ Failure Assessment (SOFA),
qSOFA and a modified version of the NIH severity scale were utilized for stratification of COVID-19 disease severity. For the NIH severity scale,
all hospitalized patients were classified as at least
moderate severity, patients requiring supplemental oxygen at presentation were considered
severe, and patients requiring intubation or vasopressors within 24 hours of admission were considered critical. We also collected data on dates of
service (including first admission date (i.e., date
of earliest inpatient encounter for COVID-19),
dates of admission to the emergency department
and inpatient ward, and discharge dates); and patient outcomes: including inpatient death (died
inpatient versus discharged alive), ventilator use
(yes/no), length of stay (days), discharge location
(home/other). Data submitted by each member
system to the Data Coordinating Center were harmonized and prepared for analysis.
Data from the CDC public use dataset (COVID-19
Case Surveillance Public Use Data with Geography.csv (N: 27,185,885) was used to show similarity of our patient population with national metropolitan patient population. The inclusion criteria
for the CDC data set were as follows: Confirmed
cases (N: 24, 481, 394); Hospitalized (N: 1,254,
128); Type 1 and 2 counties as defined by the CDC
for considering “metropolitan” area (N:1,042,150);
Time period 2020/03-2021/02 (N:917,165).
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Data Summaries and Analysis. Monthly summaries classify cases based on the date of first admission. Daily summaries are based on the total
hospital census for that day. Categorical data
were summarized as percentages and fraction of
occurrence. Continuous data were summarized
as median with interquartile range (IQR). Categorical variables for spring and fall surges were
compared by Chi-square test. Data summaries,
analysis, and visualizations were performed with
the R programming language (version 4, ggplot2
package) [20].
n RESULTS
A total of 4,775 patients were enrolled during the
study period. Data were analysed for epidemiology, patient demographics, clinical presentation,
compliance with treatment guidelines, and clinical
outcomes. The pandemic was divided into three
phases: Phase-1 (March through May 2020), representing the “Spring Surge” of cases; Phase-2 (June
through October 2020), representing the “Summer
Lull”; and Phase-3 (November 2020 through February 2021), representing the “Fall Spike”.
The total number of hospitalizations increased
sharply in Phase-1, reaching 1,043 admissions in
April 2020. A sharp decline in hospitalizations occurred over the summer months (Phase-2) with
Figure 1
Number of cases
hospitalized by month
in the United States
(Left: COVID-19 consortium;
Right: CDC).

monthly admissions ranging from 47 to 294. The
Fall Surge (Phase-3) saw monthly admissions
peak at 892 in November (Figure 1). Similar increase and decrease were seen in the national metropolitan data.
Patient demographics
Patients aged 65- to 80-years-old accounted for 30
to 40% of hospitalizations during all three phases of the pandemic. Patients aged >80 years-old
steadily increased and accounted for between
23.9%-33.7% of patients admitted during Phase
3. Patients under 40 years accounted for 7.7%19.0% of admissions during Phase 1; 8.8%-26.1%
of admissions during Phase 2 and 7.1% - 10.7%
of admissions during Phase 3. Females accounted for 47.9%-64.1% of all admissions with only
two months falling below 50%. This female predominance was most pronounced during Phase
2. African-Americans accounted for between
42.3%-64.0% of all admissions during Phase 1.
This disproportionate rate declined to 44.6%10.2% over Phase 2 and was more consistent
with Southeast Michigan demographics. During Phase 3, the proportion of hospitalized black
patients increased again to 16.5%-28.6% (Figure
2). The demographic pattern observed in our patient population was reflected on a national level
in the CDC data.
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Figure 2 - Demographic
profile of hospitalized
COVID-19 patients
in the United States
(Left: COVID-19
consortium; Right: CDC).

Clinical presentation of hospitalized COVID-19 patients
During Phase-1, patients generally presented with
shortness of breath (33.8%-59.7%) and/or cough
(14.1%-48.9%). These symptoms reached a nadir
during Phase-2 with a moderate rebound during
Phase-3. Body aches, chills, drenching sweats,
headache, nausea and vomiting were reported in
approximately 20 percent of patients during all
three phases. Loss of taste and smell, while prominent in the popular press, was reported in only
13% of patients. “Asymptomatic” patients reached
a peak of 40% of cases during Phase-2 (Table 1).
Patient co-morbidities
The prevalence of co-morbidities, reported
monthly, varied during the pandemic. Cardiac

co-morbidities included hypertension (53.3%75.5%) hyperlipidemia (33.3%-46.8%), coronary
artery disease (21.7%-34.7%), atrial fibrillation
(6.7%-17.3%) and heart failure (8.4%-21.3%). Pulmonary co-morbidities included asthma (7.1%15.8%), COPD (8.1%-9.4%) and pulmonary embolism (2.1%-7.1%). Other common co-morbidities
included diabetes (23.0%-40.8%), cancer (8.5%23.7%) and chronic kidney disease (8.5%-19.4)
(Table 2).
Medical management
The evolution of clinical management was tracked
to CDC guidelines, FDA recommendations, clinical trials, and high visibility publications and

Table 1 - Presenting symptoms for phases 1 through 3.
Symptom:
N (%)

Phase 1
(Total N: 2003)

Phase 2
(Total N: 293)

Phase 3
(Total 564: Sep. - Oct.)

p-value

Shortness of Breath

1124 (56.1)

103 (35.2)

107 (19.0)

<.0001

Cough

784 (39.1)

74 (25.3)

77 (13.7)

<.0001

Body Aches

71 (3.54)

57 (19.5)

63 (11.2)

<.0001

Chills

34 (1.70)

52 (17.7)

44 (7.80)

<.0001

Drenching Sweats

10 (0.50)

22 (7.51)

18 (3.19)

<.0001

Headache

26 (1.30)

40 (13.7)

37 (6.56)

<.0001

Nausea/Vomiting

56 (2.80)

62 (2.12)

50 (8.87)

<.0001

Loss of Taste/Smell

18 (0.90)

17 (5.80)

0 (0.0)

<.0001
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Table 2 - Comorbid conditions for phases 1 through 3.
Phase 1 (Total N: 2003)

Phase 2 (Total N: 293)

Phase 3 (Total N: 1321)

p-value

Hypertension

Comorbidity: N (%)

1417 (70.7)

180 (61.4)

834 (63.1)

<.0001

Hyperlipidemia

795 (39.7)

113 (38.6)

511 (38.7)

0.8195

Coronary Artery Disease

516 (25.8)

81 (27.6)

363 (27.5)

0.4956

Atrial Fibrillation

201 (10.0)

29 (9.90)

145 (11.0)

0.6586

Heart Failure

260 (13.0)

34 (11.6)

131 (9.91)

0.0272

Asthma

254 (12.7)

30 (10.2)

153 (11.6)

0.3821

COPD

260 (13.0)

43 (14.7)

151 (11.4)

0.2174

Pulmonary Embolism

127 (6.34)

16 (5.46)

47 (3.56)

0.0020

Diabetes

770 (38.4)

107 (36.5)

432 (32.7)

0.0034

Cancer

302 (15.1)

33 (11.3)

231 (17.5)

0.0170

Chronic Kidney Disease

305 (15.2)

27 (9.22)

124 (9.39)

<.0001

Figure 3 - Use of
hydroxychloroquine,
remdesivir,
corticosteroids
antibiotics and
anticoagulation.
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media announcements. We reviewed the use of
hydroxychloroquine, remdesivir, corticosteroids
and antibiotics use throughout the study period.
Hydroxychloroquine use rapidly accelerated
during Phase-1, reflecting early reports of benefit [5, 10]. This rise preceded the Emergency Use
Authorization (EUA) published by the Food &
Drug Administration (FDA) on March 28th [9].
At its peak, 63.4% of the patients admitted during Phase-1 received hydroxychloroquine. This
spike in treatment plateaued for a week and was
followed by a rapid decline which began prior to
the FDA revoking EUA on June 15 [10]. During
Phases 2 and 3, there was sporadic use of hydroxychloroquine (Figure 3 Panel 1).
Remdesivir was first reported to be of benefit in
vitro against COVID-19 in February of 2020 (5). A
subsequent clinical trial demonstrated benefit and
the FDA released an EUA on May 1st, 2020 [11].
Our data demonstrate very little use of remdesivir
during Phase-1 of the pandemic. Use of remdesivir began early in Phase-2 and approached 50% of
hospitalized patients by September. This rise appears to precede FDA approval of remdesivir for
COVID-19 but was contemporary with published
reports of efficacy (Figure 3 Panel 2) (12). Remdesivir use persisted throughout Phase 3.
The potential benefits of corticosteroid use in
COVID-19 patients requiring mechanical ventilation or supplemental oxygen was reported by the
RECOVERY Collaborative Group in July 2020 [4,
14]. In our study, corticosteroid use was prevalent
throughout all three phases. Early in Phase 1, steroid use peaked at 56.1%, declining to 38.5% by
April 2020. After the NIH recommended against
steroid use, there was a sharp decline of steroids
use in May [23]. After the June 16th press release
by the RECOVERY trial of a mortality benefit, steroid use increased sharply again to above 50% of
the patients, stabilizing during Phase 3 at 50-75%
(Figure 3 Panel 3) [15].
Antibiotic use for COVID-19, particularly azithromycin, was reported to be of benefit in March
2020 [9]. On May 12th, the NIH stated there was
insufficient data to support use of antibiotics for
COVID-19 patients. Subsequent studies documenting independent use of azithromycin in
late-stage hospitalized COVID-19 patients did
not show benefit [16-18]. In our study, antibiotics
were prescribed in almost half of all patients admitted for COVID-19 during Phase 1. Use rates

varied widely during Phase 2 but levelled off to
25-30% of patients in Phase 3 (Figure 3 Panel 4).
Prophylactic and therapeutic anticoagulation of
hospitalized patients evolved during the pandemic. As reports of elevated D dimer, COVID
associated thromboembolic disease poor prognosis of patients with abnormal coagulation
markers and benefit of anticoagulation were reported, the use of anticoagulation rose [24, 25].
During Phase 1 monthly rates of prophylaxis
ranged between 25%-66.7%. During Phase 2
prophylactic anticoagulation rose. During Phase
3 monthly rates ranged between 40%-70.4%.
Therapeutic doses of anticoagulation started
increasing sharply after the report of increased
thromboembolism [26]. During Phase 1 between
28.0%-55.2% of the patients received therapeutic
doses of anticoagulation. During Phases 2 and 3
anticoagulation fluctuated between 11%-79.5%
(Figure 3 Panel 5).
Clinical outcomes
All three severity scales (i.e., SOFA, qSOFA and
modified NIH), had similar receiver operating
characteristic curves for mortality (AUC, 0.77,
0.74, 0.77, respectively). We used the modified
version of the NIH severity scale to display the
severity data when comparing the three phases.
Patients presenting in a critical state were more
common at the start of the pandemic and this
declined as the number of cases hospitalized decreased. This number has been increasing steadily
as the number of hospitalizations has increased.
During Phase-1, monthly intubation rates ranged
from 14.1% to 24.8%. Intubation rates fell to of
0.0% in June (Phase-2) but rose steadily over the
summer and plateaued at 9.2% in Phase-3 (Figure
4; Table 3).
Mortality rates paralleled intubation rates.
Monthly mortality rates ranged between 14.8%21.5% of hospitalized patients during Phase-1.
Mortality declined to 2.1% early in phase-2 but
slowly increased over the summer to 12.6%. By
late fall (Phase-3) monthly mortality ranged between 9.7 and 13.4% (Figure 4). A similar decrease
followed by increase in mortality is seen in the
national CDC data. Mortality rates varied by NIH
score. Monthly mortality rates for patients classified moderate (0.0%-13%) to severe (0.0%-17%)
COVID remained similar for all three phases. Patients classified as critical had much higher mor-
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tality rates. Mortality in critically ill patients rose
significantly from Phase-1 to III (47.9% vs 60.3%
Chisq p=0.0110) (Figure 5; Table 3).
A large number (>80%) of COVID-19 hospitalization survivors were discharged to sites of care

other than home at the onset of the pandemic. As
the pandemic progressed, this decreased to 45.6%
in May but increased again before stabilizing at a
level of approximately 69-86.3% of patients from
July onwards.

Figure 4 - Percent of hospitalized patients that were intubated/died (Left: COVID-19 consortium) and percent
mortality in all hospitalized patients/ hospitalized patients with known confirmed outcome (excluding patients
with unknown or missing mortality status) (Right: CDC data).
Table 3 - Intubation rates, in-hospital mortality and mortality by NIH Severity Score.
Phase 1
(Total N: 2003)

Phase 2
(Total N: 293)

Phase 3
(Total N: 1320)

p-value

In-Hospital Intubation

373 (18.6)

In-Hospital Death

406 (20.3)

12 (4.10)

110 (8.33)

<.0001

19 (6.48)

134 (10.2)

<.0001

28/442 = 6.33%

4/122 = 3.28%

23/413 = 5.57%

0.4304

Severe

159/1198 = 13.3%

5/152 = 3.29%

38/773 = 4.92%

<.0001

Critical

219/363 = 60.3%

10/19 = 52.6%

73/135 = 54.1%

0.3951

Outcome: N (%)

Mortality by NIH
Severity
Score
Moderate
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Figure 5 - Mortality by
NIH Severity Score.

n DISCUSSION
The Southeast Michigan (SE) counties of Wayne,
Oakland, and Macomb have been an epicenter
for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, accounting
for more than 40% of the state’s disease burden.
A consortium two health care systems involving
six regional hospitals collected data from patients
with PCR-confirmed COVID-19 over a one-year
period. The pandemic was divided into three
distinct phases based on number of admissions,
patient characteristics, treatments and presentations.
The Spring Surge (Phase-1) was characterized by
a large volume of admissions, a high intubation
(14.1%-24.8%) and mortality rate (14.8%-21.5%).
The Summer Lull (Phase-2) was characterized by
few admissions, and low intubations and mortality rates. Phase-3 saw a resurgence of admissions,
which did not reach the peak achieved in Phase-1,
and a rebound in intubation (8.0%-9.5%) and
mortality (9.7%-13.4%) rates. The same pattern
was seen in all metropolitan areas captured in
the CDC data. This shows that our metropolitan
patient population can serve as a representative
sample for the national metropolitan population.

Thus, the clinical characteristics, comorbidities
and medication usage pattern that we observe in
our patient population (features that cannot be
studied in a national data set) can also be generalized to any metropolitan population in the US
(and possibly anywhere in the world). Comorbidities were similar in all three phases [22].
In our data set, we found our most commonly reported symptoms - cough, dyspnoea, and fever
- were similar to those reported in larger studies
[22]. However, we found that the incidence of all
of these common COVID-19 symptoms declined
over the study period. Respiratory symptoms became less common in the later months, with an
associated increase in the rate of gastrointestinal
and systemic symptoms. Less than 13% of patients reported loss of taste or smell in all three
Phases. The cause of these trends is unclear. Potential explanations for these findings include
surges in different viral variants with a predilection for different organ systems, differences in patient susceptibility to the virus (e.g., patients predisposed to respiratory symptoms contracting the
virus earlier in the study period), or differences in
symptom reporting by patients or providers [26].
Between 9.9%-40.4% of Phase-2 patients had no
symptoms. We believe that this lack of symptoms
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reflected testing of all hospital admissions, including elective surgeries and patients admitted
for non-COVID related illnesses.
Demographics demonstrated slightly more than
half of COVID admissions were female. African
Americans represented approximately two thirds
of admissions during Phase-1. This dropped to
less than 20% during phase-2 with a rise to 30%
during Phase-3. The cause for these disproportionate representations is not clear and requires
further study.
Age distribution remained similar during all
three phases with a slight increase in patients over
80 years old during Phase-3.
The reduction in intubation and mortality may
be the result of increased comfort and knowledge in management, improved treatment protocols or variation in virus strains. Medical interventions evolved quickly in response to studies
published in the medical literature and often
preceded CDC and NIH recommendations. This
rapid response suggests hospital medical leadership reviewed evolving data and modified treatment protocols based on evidence published in
the literature prior to CDC, NIH or FDA recommendations.
In this data set, the qSOFA, SOFA and NIH severity scales appear to be very good predictors
of mortality. Intubation and mortality rates for
hospitalized patients fell from Phase-1 to Phase-3.
Despite this improvement, both remained approximately 10% in Phase-3. Strategies to reduce
hospitalizations should be emphasized.
The study strengths include a large number of patients representing diverse ethnic, economic, racial
and sex backgrounds. Secondly, both hospital systems utilize EPIC for their electronic health records
(EHR). Data were extracted from each institution’s
EHR into a common database for analysis.
The study is limited by lack of rural representation. Although the study only includes one metropolitan area the authors believe the findings can
be applicable to any typical metropolitan area as
the patient characteristics were similar to those
in the CDC database. Medical practice in participating hospitals would be typical for what would
be seen in a mix of academic and community
hospitals anywhere in the country. The database
contains patients managed by a large number of
independent physicians across multiple hospitals
and hence it is generalizable.

In conclusion, the COVID-19 pandemic in Southeast
Michigan can be broken down into three distinct
phases. Each phase was characterized by unique
demographics, presentations, treatment regimens
and outcomes. Treatment regimens quickly evolved
in response to medical literature and frequently
preceded NIH or CDC recommendations.
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